TABLE 2.
Production of cytokines IL-2, IL-5, and IFN-γ by PBMC stimulated with recombinant CT-B from the three study groups and all three groups combined
| Group (n) | Mean cytokine production (pg/ml [range])a of:
|
|||||
|---|---|---|---|---|---|---|
| IL-2
|
IFN-γ
|
IL-5
|
||||
| Before | After | Before | After | Before | After | |
| U.S. controls (8) | 9.8 (0–52.7) | 38.0 (0–210.4) | 0 (0–15.3) | 28.3 (0–85.0) | 17.8 (0–50.4) | 0 (0–38.6) |
| A. lumbricoides infected | ||||||
| Placebo (13) | 0 (0–20.9) | 0 (0–252.9) | 0 (0–30.0) | 7.9 (0–298.2) | 0 (0–10.5) | 0 (0–30.3) |
| Albendazole (15) | 0.3 (0–55.8) | 21.8 (0–74.0) | 0 (0–54.0) | 7.7 (0–209.7) | 0 (0–22.7) | 0 (0–25.3) |
| All infected (28) | 0 (0–55.8) | 0 (0–252.9) | 0 (0–54.0) | 7.7 (0–298.2) | 0 (0–22.7) | 0 (0–30.3) |
| Total (all groups) (36) | 0 (0–55.8) | 1.4 (0–252.9) | 0 (0–54.0) | 8.5 (0–298.2) | 0 (0–50.4) | 0 (0–38.6) |
a
Shown are the median values and ranges for cytokine production levels before vaccination with CVD 103-HgR (before) and at 14 days postvaccination (after). Prevaccination cytokine levels are the median value of the mean of the two prevaccination observation times (before albendazole or placebo treatment and after two doses of albendazole or placebo).